Bank of America Corp (NYSE:BAC) allocates millions each year to provide GLP-1 obesity medications for employees, with CEO Brian Moynihan calling it an investment in workforce health and productivity.
"We spend about $250 million or more on GLPs, and that’s up from zero" four or five years ago, the CEO told CNBC on Wednesday.
"We see a great impact on the employees," he added.
The bank spends more than $2 billion annually on employee healthcare, with GLP-1 medications accounting for about 13% of that total.
It combines GLP-1 medication coverage with health coaching to support weight management and lifestyle changes.
